Svb Leerink reaffirmed their outperform rating on shares of Neovasc (TSE:NVC) (NASDAQ:NVCN) in a research note issued to investors on Friday, Zacks.com reports. Svb Leerink also issued estimates for Neovasc’s Q2 2019 earnings at $0.00 EPS, Q3 2019 earnings at $0.00 EPS, Q4 2019 earnings at $0.00 EPS, Q2 2020 earnings at $0.00 EPS, Q3 2020 earnings at $0.00 EPS and Q4 2020 earnings at $0.01 EPS.
Neovasc has a 1-year low of C$0.49 and a 1-year high of C$1.82.
Neovasc (TSE:NVC) (NASDAQ:NVCN) last posted its quarterly earnings data on Thursday, March 21st. The company reported C($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of C($0.13) by C($0.07). The business had revenue of C$0.69 million during the quarter, compared to analysts’ expectations of C$0.60 million.
Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.
Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with MarketBeat.com's FREE daily email newsletter.